Principal Investigator:<\/strong><\/p>\n\n\n\n Michel Savard<\/strong> Among the challenges facing the pharmaceutical industry are high attrition rates and the need to assess the success of clinical trials in the light of the risk factors inherent in the drug development process. In fact, less than 10% of potential drugs entering Phase 1 trials will ever reach the market.\u00a0 These risk factors contribute to failures in the later phases of clinical development, and it would be beneficial to detect them as early as possible to enable the various stakeholders to make the decisions necessary to prevent failure.<\/p>\n\n\n\n Sorintellis, in collaboration with Vantage Biotrials and the Computer Research Institute of Montreal (CRIM), previously developed a proof of concept for a priori estimation of clinical trial success.\u00a0 As part of this project, the research team is pursuing the development of a predictive risk assessment and analysis platform for the conduct of clinical trials, drawing on its expertise in the development of artificial intelligence (AI) solutions. This platform will be integrated into a large database developed by Sorintellis and will be based on a rigorous development protocol enabling the development of an innovative prescriptive approach that goes beyond the “black box” nature of many machine learning approaches, thus providing an indispensable tool for strategic decision-making.<\/p>\n\n\n\n Through this collaborative research project, Sorintellis and the CRIM research team aim to offer pharmaceutical companies and contract research organizations cutting-edge technology to support complex decision-making processes in the planning and efficient conduct of clinical trials.\u00a0 In terms of AI innovation, the approaches evaluated will enable several interpretability techniques to be assessed, facilitating the development of trusted AI systems in new fields. For Quebec, this is an opportunity to develop cutting-edge technology that will energize the pharmaceutical industry and reinforce our global leadership in the conduct of clinical trials, while leveraging the strength of our AI ecosystem.<\/p>\n","protected":false},"featured_media":3820,"template":"","project-category":[95],"class_list":["post-4055","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-bioinformatics-and-artificial-intelligence"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/4055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3820"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=4055"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=4055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/strong>CRIM<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\nProject of $323,390 over 18 months<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n
\n
Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n\n
\n\n\n\nChallenge<\/strong><\/h2>\n\n\n\n
Solution <\/h2>\n\n\n\n
Achievements\/Impact<\/strong><\/h2>\n\n\n\n